Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist

Company Anticipates Initiating Phase 2a Studies by Early 2012

SAN DIEGO, May 2, 2011 - Amira Pharmaceuticals, Inc. announced today initial positive data from a
Phase 1 clinical study of AM152, the Company's oral selective antagonist of
the LPA1 receptor. Completion of this study positions Amira to initiate a
Phase 2a study in patients suffering from systemic sclerosis, a systemic
fibrotic disease, by early 2012.

"The Phase 1 clinical study in healthy volunteers demonstrated that AM152
is safe and well-tolerated at doses which are expected to provide a full
range of receptor coverage in humans," said Isabelle DeArmond, Vice
President, Clinical Development. "These results enable us to study AM152 at a
wide range of doses in patients suffering from fibrotic diseases."

Bob Baltera, Chief Executive Officer, added, "Initiating a Phase 2a study
in patients suffering from systemic sclerosis will be an important milestone
for the team at Amira; we look forward to better understanding the potential
therapeutic benefit of AM152."

AM152 is a novel LPA1 receptor antagonist developed by the scientists at
Amira. Preclinical data has demonstrated that antagonism of the LPA1 receptor
inhibits fibrosis in several disease models. Much of these data has been
previously presented and published by Amira scientists and colleagues. Amira
Pharmaceuticals also recently announced that AM152 was granted Orphan Drug
Status by the FDA for patients suffering from idiopathic pulmonary fibrosis
(IPF).

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is
a small molecule pharmaceutical company focused on the discovery and early
development of new drugs to treat inflammatory and fibrotic diseases. Amira
combines the rigor of a big pharmaceutical company with the ingenuity and
energy of a small company, creating an environment for efficient development
of novel compounds and effective pre-clinical and clinical program decisions.
Our team is building on unparalleled insights into bioactive lipid pathways
and complex signaling processes controlling many conditions including asthma,
chronic obstructive pulmonary disease, cardiovascular and various fibrotic
diseases. Amira has a partnership with GlaxoSmithKline for the development of
FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and
cardiovascular disease. For more information, visit www.amirapharm.com.

    Media Contact
    Ian Stone
    Russo Partners
    Tel: +1-619-528-2220
    ian.stone@russopartnersllc.com

.